SG186388A1 - A combination composition comprising ibuprofen and paracetamol - Google Patents
A combination composition comprising ibuprofen and paracetamol Download PDFInfo
- Publication number
- SG186388A1 SG186388A1 SG2012093183A SG2012093183A SG186388A1 SG 186388 A1 SG186388 A1 SG 186388A1 SG 2012093183 A SG2012093183 A SG 2012093183A SG 2012093183 A SG2012093183 A SG 2012093183A SG 186388 A1 SG186388 A1 SG 186388A1
- Authority
- SG
- Singapore
- Prior art keywords
- approximately
- ibuprofen
- paracetamol
- composition
- combination
- Prior art date
Links
- 229960001680 ibuprofen Drugs 0.000 title claims abstract description 63
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims abstract description 61
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 229960005489 paracetamol Drugs 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 206010061218 Inflammation Diseases 0.000 claims abstract description 7
- 230000004054 inflammatory process Effects 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 22
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- GCCOJNYCFNSJII-VWMHFEHESA-N [n'-[(4s)-4-amino-4-carboxybutyl]carbamimidoyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N.CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 GCCOJNYCFNSJII-VWMHFEHESA-N 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IHHXIUAEPKVVII-ZSCHJXSPSA-N [(1s)-5-amino-1-carboxypentyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound OC(=O)[C@@H](N)CCCC[NH3+].CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1 IHHXIUAEPKVVII-ZSCHJXSPSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A combination composition for providing relief for pain and/or inflammation, the composition having ibuprofen and paracetamol and being suitable for use in delivering to a human intravenously at each dose: a) approximately 375 mg to approximately 425 mg ibuprofen, in combination with approximately 975 mg to approximately 1,025 mg paracetamol; or b) approximately 175 mg to approximately 225 mg ibuprofen, in combination with approximately 475 mg to approximately 525 mg paracetamol.
Description
A COMBINATION COMPOSITION COMPRISING IBUPROFEN AND PARACETAMOL
This invention relates to a combination composition comprising paracetamol and ibuprofen. A particularly preferred embodiment of the invention relates to a combination composition comprising these as active ingredients for use in relieving pain and/or inflammation.
Combinations of paracetamol and ibuprofen are known, for example as relatively low dose tablets having 150 mg ibuprofen and 500 mg. However there is a need for a medication, particularly one which can be administered intravenously in a hospital environment, which delivers higher doses of ibuprofen to provide pain relief in cases of severe or extreme pain. It is an object of one embodiment of the present invention to go at least some way towards facilitating this. :
References in this specification to an adult mean a person weighing 50 kg or more.
References in this specification to a child mean a person weighing less than 50 kg.
The term “comprising” and derivatives thereof, eg “comprises”, if and when used herein in relation to a combination of features should not be taken as excluding the possibility that the combination may have further unspecified features.
According to one aspect of the invention there is provided a composition for providing relief for pain and/or inflammation, the composition having ibuprofen and paracetamol in combination for delivering to a human at each dose: a) approximately 375 mg to approximately 425 mg ibuprofen, b) approximately 575 mg to approximately 625 mg ibuprofen, c) approximately 175 mg to approximately 225 mg ibuprofen, or d) approximately 275 mg to approximately 325 mg ibuprofen,
in the case of option a) or b) in combination with approximately 975 mg to approximately 1,025 mg paracetamol, or in the case of options c) or d) in combination with approximately 475 mg to approximately 525 mg paracetamol.
Optionally the composition is for delivering to the human (preferably an adult) at each dose approximately 400 mg ibuprofen and approximately 1,000 mg paracetamol.
Optionally the composition is for delivering to the human (preferably an adult) at each dose approximately 600 mg ibuprofen and approximately 1,000 mg paracetamol.
Optionally the composition is for delivering to a child at each dose approximately 200 mg ibuprofen and approximately 500 mg paracetamol.
Optionally the composition is for delivering to a child at each dose approximately 300 mg ibuprofen and approximately 500 mg paracetamol.
Optionally the composition is for delivering the ibuprofen and paracetamol to the human (eg a child or adult) intravenously.
Optionally the composition is in the form of a solution.
Optionally the composition is in the form of a suspension.
A further aspect of the invention involves the use of ibuprofen and paracetamol in the manufacture of a medicament for treating pain and/or inflammation in a human, the medicament having: a) approximately 375 mg to approximately 425 mg ibuprofen, b) approximately 575 mg to approximately 625 mg ibuprofen, c) approximately 175 mg to approximately 225 mg ibuprofen, or d) approximately 275 mg to approximately 325 mg ibuprofen, in the case of option a) or b) in combination with approximately 975 mg to approximately 1,025 mg paracetamol, or in the case of options c) or d) in combination with approximately 475 mg to approximately 525 mg paracetamol.
Optionally the medicament has approximately 400 mg ibuprofen and approximately 1,000 mg paracetamol. In this instance the medicament may be for treating an adult.
Optionally the medicament has approximately 600 mg ibuprofen and approximately 1,000 mg paracetamol. In this instance the medicament may be for treating an adult.
Optionally the medicament is for treating a child and has approximately 200 mg ibuprofen and approximately 500 mg paracetamol.
Optionally the medicament is for treating a child and has approximately 300 mg ibuprofen and approximately 500 mg paracetamol.
Optionally the medicament is for intravenous administration.
Optionally the composition is in the form of a solution. :
Optionally the composition is in the form of a suspension.
According to a further aspect of the invention there is provided a method of treating a human to relieve pain and/or inflammation, comprising administering to the human: a) approximately 375 mg to approximately 425 mg ibuprofen, b) approximately 575 mg to approximately 625 mg ibuprofen, c) approximately 175 mg to approximately 225 mg ibuprofen, or d) approximately 275 mg to approximately 325 mg ibuprofen, in the case of option a) or b) in combination with approximately 975 mg to approximately 1,025 mg paracetamol, or in the case of options c) or d) in combination with approximately 475 mg to approximately 525 mg paracetamol.
Optionally approximately 400 mg ibuprofen and approximately 1,000 mg paracetamol are administered to the human per dose. In this instance the human is preferably an adult.
Optionally approximately 600 mg ibuprofen and approximately 1,000 mg paracetamol are administered to the human per dose. In this instance the human is preferably an adult.
Optionally approximately 200 mg ibuprofen and approximately 500 mg paracetamol are administered to a child per dose.
Optionally approximately 300 mg ibuprofen and approximately 500 mg paracetamol are administered to a child per dose.
Optionally the composition is administered to the human (eg an adult or child) intravenously. i
Optionally the composition is in the form of a solution. | :
Optionally the composition is in the form of a suspension.
In a preferred embodiment of the invention an intravenous solution is provided for use in treating severe pain in human patients. The solution is a combination medication comprising ibuprofen, paracetamol, purified water and suitable excipients as will be known to those with ordinary skills in the art of formulating intravenous medicines.
The excipients may be standard and may include one or more of suspending agents, viscosity regulating agents, buffering agents, wetting agents, preservatives, sweetening agents, flavouring agents and solvents.
The following examples illustrate preferred embodiments of the invention in the form of intravenous infusion solutions although the invention should not be seen as limited to these.
}
Ingredient Example 1 Example 2 Example 3 Example 4 : mg/ 100ml vial | mg/ 100mi vial | mg/ 50ml vial | mg/ 50ml vial
For each of the above examples the two active ingredients are mixed with suitable amounts of the following excipients to give the vial volumes indicated in the above table: e Cysteine hydrochloride monohydrate e Disodium phosphate dehydrate e Mannitol e¢ Hydrochloric acid e Sodium hydroxide e Purified water
Further examples of intravenous infusion solutions are provided below
Ingredient Example 5 Example 6 (adult dose) (child dose)
Ibuprofen arginine 737 mg 368 mg (active ingredient) (corresponds to 400 mg (corresponds to 200 mg ibuprofen) ibuprofen)
Paracetamol 1,000 mg 500 mg (active ingredient)
Reduced glutathione 20 mg 120mg (antioxidant)
Sodium hydroxide or Sufficient to give a | Sufficient to give a pH hydrochloric acid pH of 5-6 of 5-6 (pH modulator)
Sodium citrate 10 mg 10 mg (buffering agent)
Sodium chloride Sufficient to impart Sufficient to impart (isotonicity agent) isotonicity isotonicity
Purified water Sufficient to bring Sufficient to bring the the composition to composition to 100 ml 100 ml
All of the above infusion solutions are for delivery to a patient as a full dose, for example in each case the patient receives the complete vial contents as a 15 minute infusion every 6 hours. Examples 1, 2 and 5 are each an adult dose and Examples 3, 4 and 6 are each a child dose. In the case of very young or small children only part of the vial contents of Examples 3, 4 and 6 may be dosed, commensurate with instructions from the prescribing physician. :
Paracetamol at 4,000 mg per 24 hour period, taken in 4 doses of 1,000 mg every 6 hours, has long been considered sufficient for relieving low level pain but for many patients suffering significant pain, for example in some post-operative situations, it is not sufficient. However it is generally not advisable to dose paracetamol at more than 1,000 mg per dose or at more than 4,000 mg per 24 hour period, because to do so can lead to undesirable side effects.
It is known to treat severe pain with ibuprofen in doses of 800 mg every 8 hours.
However, doses as high as 800 mg can lead to undesirable side effects, for example adverse cardio renal conditions, thrombotic risks and gastrointestinal bleeding.
Reducing the amount of ibuprofen at each dosing event may reduce the risk of side affects but at the same time may provide substantially less pain relief.
Surprisingly, a combination medicine comprising 600 mg or 400 mg ibuprofen, plus 1,000 mg paracetamol, for use every 6 hours, provides adequate pain relief for some patients that would otherwise take 800 mg ibuprofen every 8 hours. The lower dose of ibuprofen, ie 600 mg or 400 mg, versus 800 mg; may reduce the risk of undesirable side affects but the effectiveness of the medication is for such patients not compromised due to the presence of the paracetamol. This is unexpected because one would not predict the presence of paracetamol at only 1,000 mg per dose to assist to any significant degree. The combination is counterintuitive because 800 mg ibuprofen for relief of severe pain is generally seen as an 8 hourly medicament, and 1,000 mg paracetamol is generally seen as a 6 hourly medicament for treating lower level pain. The normal dosage regimens for these active ingredients are out of step with one another, ie 8 hourly versus 6 hourly, and thus to the normally skilled artesian they would not, at the doses of the present invention, be seen as suitable for a combination medication.
Similar considerations apply in the case of 200 mg or 300 mg ibuprofen, in combination with 500 mg paracetamol, for treating children suffering from severe pain. In this regard, surprisingly, some children that would normally be given 400 mg ibuprofen for severe pain can be given, as an alternative, 200 mg or 300 mg ibuprofen, in combination with 500 mg paracetamol.
ALTERNATIVE CHEMICAL FORMS
While ibuprofen and paracetamol are specifically referred to in this specification, suitable other pharmaceutically acceptable forms of these two actives (eg salts, etc) may also be used and are intended to be embraced in the claims by references to the actives per se, with the weight amounts adjusted accordingly. For example, when a salt form is used, sufficient quantity may be included to meet the desired amount of the compound per se (eg, 200 mg ibuprofen corresponds with 368 mg ibuprofen arginine, or 342 mg ibuprofen lysinate). Thus, for example, a reference to 200 mg ibuprofen may be construed as sufficient to embrace the therapeutically equivalent amount of ibuprofen arginine or ibuprofen lysinate.
While some preferred forms of the invention have been described by way of example it should be appreciated that modifications and improvements can occur without departing from the scope of the appended claims.
Claims (16)
1. A combination composition for providing relief for pain and/or inflammation, the composition having ibuprofen and paracetamol and being suitable for use in delivering to a human intravenously at each dose: a) approximately 375 mg to approximately 425 mg ibuprofen, in combination with approximately 975 mg to approximately 1,025 mg paracetamol; or b) approximately 175 mg to approximately 225 mg ibuprofen, in combination with approximately 475 mg to approximately 525 mg paracetamol.
2. A composition according to claim 1, for delivering to the human at each dose approximately 400 mg ibuprofen and approximately 1,000 mg paracetamol.
3. A composition according to claim 2, wherein the human is an adult.
4. A composition according to claim 1, for delivering to a child at each dose approximately 200 mg ibuprofen and approximately 500 mg paracetamol.
5. A composition according to any one of claims 1 to 4, in the form of a solution.
6. A composition according to any one of claims 1 to 4, in the form of a solid suitable for mixing with a fluid to provide a solution.
7. A composition according to claim 1, for intravenous administration on a 12.5 mg : paracetamol per kg body weight basis.
8. A composition according to claim 7, for administration every 6 hours.
9. The use of ibuprofen and paracetamol in the manufacture of a combination medicament for treating pain and/or inflammation in a human by intravenous administration, the medicament having:
a) approximately 375 mg to approximately 425 mg ibuprofen, in combination with approximately 975 mg to approximately 1,025 mg paracetamol; or b) approximately 175 mg to approximately 225 mg ibuprofen, in combination with 475 mg to 525 mg paracetamol.
10. A use according to claim 9, wherein the medicament has approximately 400 mg ibuprofen and approximately 1,000 mg paracetamol.
11. A use according to claim 10, wherein the medicament is for treating an adult.
12. A use according to claim 9, wherein the medicament is for treating a child and has approximately 200 mg ibuprofen and approximately 500 mg paracetamol.
13. A use according to any one of claims 9 to 12, wherein the composition is in the form of a solution.
14. A use according to any one of claims 9 to 12, wherein the composition is in the form of a solid suitable for mixing with a fluid to provide a solution.
15. A use according to claim 9, wherein the composition is for intravenous administration on a 12.5 mg paracetamol per kg body weight basis.
16. A use according to claim 15, wherein the composition is for administration every 6 hours.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ58666110 | 2010-07-07 | ||
| PCT/NZ2011/000117 WO2012005605A1 (en) | 2010-07-07 | 2011-06-21 | A combination composition comprising ibuprofen and paracetamol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG186388A1 true SG186388A1 (en) | 2013-01-30 |
Family
ID=45441395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012093183A SG186388A1 (en) | 2010-07-07 | 2011-06-21 | A combination composition comprising ibuprofen and paracetamol |
Country Status (6)
| Country | Link |
|---|---|
| AU (1) | AU2011274652B2 (en) |
| MY (1) | MY164112A (en) |
| NZ (1) | NZ604009A (en) |
| SG (1) | SG186388A1 (en) |
| WO (1) | WO2012005605A1 (en) |
| ZA (1) | ZA201208210B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107519159A (en) * | 2010-11-04 | 2017-12-29 | 阿福特药物有限公司 | Compound |
| CN103565733A (en) * | 2012-07-31 | 2014-02-12 | 南京帝易医药科技有限公司 | Ibuprofen sodium chloride injection preparation with pH of 6.0-6.5, and preparation method thereof |
| US11197830B2 (en) | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
| WO2023281089A2 (en) | 2021-07-08 | 2023-01-12 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising naproxen and paracetamol |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1781277B1 (en) * | 2004-07-07 | 2012-02-01 | AFT Pharmaceuticals Limited | A combination composition comprising ibuprofen and paracetamol |
| US20090264530A1 (en) * | 2008-04-16 | 2009-10-22 | Nickell Robert P | Combined nsaid and acetaminophen formulation and method |
-
2011
- 2011-06-21 MY MYPI2012005317A patent/MY164112A/en unknown
- 2011-06-21 NZ NZ60400911A patent/NZ604009A/en unknown
- 2011-06-21 WO PCT/NZ2011/000117 patent/WO2012005605A1/en active Application Filing
- 2011-06-21 SG SG2012093183A patent/SG186388A1/en unknown
- 2011-06-21 AU AU2011274652A patent/AU2011274652B2/en active Active
-
2012
- 2012-12-06 ZA ZA2012/08210A patent/ZA201208210B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY164112A (en) | 2017-11-30 |
| NZ604009A (en) | 2015-03-27 |
| ZA201208210B (en) | 2014-04-30 |
| WO2012005605A1 (en) | 2012-01-12 |
| AU2011274652A1 (en) | 2013-01-10 |
| AU2011274652B2 (en) | 2013-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11896567B2 (en) | Combination composition | |
| JP6738376B2 (en) | Method of treating bendamustine-responsive symptoms in patients in need of reduced dosing volume | |
| US20200179351A1 (en) | Treatment of depressive disorders | |
| AU2011274652B2 (en) | A combination composition comprising ibuprofen and paracetamol | |
| US20110028553A1 (en) | Treating critically ill patients with intravenous ibuprofen | |
| KR20120089444A (en) | Treating critically ill patients with intravenous ibuprofen | |
| AU2017305661B2 (en) | New use of N,N-bis-2-mercaptoethyl isophthalamide | |
| Vermeulen et al. | Feasibility of long-term continuous subcutaneous magnesium supplementation in a patient with irreversible magnesium wasting due to cisplatin | |
| WO2012156502A2 (en) | Two component mouth rinse preparation | |
| BR112021009365A2 (en) | stable glucocorticoid formulation | |
| WO2014150318A1 (en) | Therapeutic agent for enhancing mitochondrial function |
